BioCardia initiates patient enrollment at University of Wisconsin for CardiAMP HF II Phase 3 trial

BioCardia, Inc.

University of Wisconsin now enrolling ischemic HFrEF patients in BioCardia's pivotal Phase 3 CardiAMP HF II trial.
Dr. Amish Raval named site PI and co-national PI for the study.
Trial uses autologous cell therapy with a three-tier composite outcome: death, nonfatal MACE, and quality-of-life.
Prior CardiAMP HF study met composite endpoint in elevated NTproBNP patients (p=0.02).
Advances include cell population analysis for dosing and FDA-approved Morph DNA steerable platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.